Results 81 to 90 of about 9,340 (184)

Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)

Advances in Therapy
The Nucala Effectiveness Study (NEST) assessed the effectiveness of mepolizumab in patients with severe asthma (SA) in countries previously underrepresented in real-world studies.
R. Al-Lehebi, M. Al Ahmad, V. N. Maturu, Alejandra Galeano Mesa, B. Mahboub, E. Garcia, P. Fernandez, Claudia Soares, Gabriela Abreu, Debora Dos Santos, Juliana Queiroz, A. Raimondi, M. Laucho-Contreras, S. Noibi, Gur Levy, S. Bavbek   +15 more
semanticscholar   +1 more source

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

Journal of Asthma and Allergy, 2023
Stephanie Korn,1 Katrin Milger,2 Dirk Skowasch,3 Christian Schulz,4 Cordula Mohrlang,5 Martin Wernitz,5 Thomas Paulsson,6 Michael Hennig,5 Roland Buhl7 1IKF Pneumologie Mainz, Mainz and Thoraxklinik Heidelberg, Heidelberg, Germany; 2Department of ...
Korn S, Milger K, Skowasch D, Schulz C, Mohrlang C, Wernitz M, Paulsson T, Hennig M, Buhl R   +8 more
doaj  

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

Annals medicus
Background Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients’ characteristics are different from those encountered in asthma ...
M. Basagaña, Carlos Martínez-Rivera, Clara Padró, I. Garcia-Olivé, Mimar Martínez-Colls, Juan Navarro, Laura Pardo, Paula Cruz, G. Cardona Peitx, Lídia Carabias, Albert Roger, Jorge Abad, Antoni Rosell   +12 more
semanticscholar   +1 more source

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Journal of Asthma and Allergy, 2020
Jared Silver,1 Michael Bogart,1 Elizabeth Packnett,2 Juan Wu,2 Donna McMorrow,2 Beth Hahn1 1US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Life Sciences, IBM Watson Health, Bethesda, MD, USACorrespondence: Beth Hahn Email beth.a.hahn@gsk ...
Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B   +5 more
doaj  

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Frontiers in Medicine
Introduction Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity.
C. Desaintjean, K. Ahmad, J. Traclet, M. Gerfaud-Valentin, C. Durel, J. Glérant, A. Hot, F. Lestelle, Sabine Mainbourg, M. Nasser, P. Sève, S. Turquier, G. Devouassoux, V. Cottin   +13 more
semanticscholar   +1 more source

Effects of Mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study

European Archives of Oto-Rhino-Laryngology
Mepolizumab was recently approved for treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) unresponsive to standard treatment or recurring after endoscopic sinus surgery (ESS).
P. Orlando, E. Vivarelli, A. Minzoni, G. Licci, M. Accinno, B. Brugnoli, A. Matucci, A. Vultaggio, G. Maggiore   +8 more
semanticscholar   +1 more source

Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study

Journal of Allergy and Clinical Immunology: Global
Background: Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Juan Carlos Cardet, MD, MPH, Jared Silver, MD, Martin Maldonado-Puebla, MD, François Laliberté, MA, Chi Gao, PhD, Ramya Ramasubramanian, PhD, Annalise Hilts, BA, Kaixin Zhang, MSc, Jeremiah Hwee, PhD, Waseem Ahmed, MBA, Amy G. Edgecomb, PharmD, MPH   +10 more
doaj   +1 more source

Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

ERJ Open Research
Background In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China.
Ruchong Chen, Liping Wei, Y. Dai, Zaiyi Wang, Danrong Yang, M. Jin, Cui Xiong, Ting Li, Shuling Hu, Jie Song, R. Chan, Subramanya Kumar, Azza Abdelkarim, Nanshan Zhong   +13 more
semanticscholar   +1 more source

Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma

European Respiratory Journal
Graphical abstract Overview of the study. OCS: oral corticosteroid; ACQ-5: Asthma Control Questionnaire (5-item); FEV1: forced expiratory volume in 1 s. Background Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit ...
Yuto Hamada, Dennis Thomas, E. Harvey, S. Stevens, M. Fricker, H. Lewthwaite, Vanessa M. McDonald, Andrew Gillman, M. Hew, V. Kritikos, J.W. Upham, P. Gibson   +11 more
semanticscholar   +1 more source

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report

Journal of Medical Case Reports
Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin ...
M. Sabbe, F. Schleich, P. Janssens, R. Louis   +3 more
doaj   +1 more source